Syndax Pharmaceuticals, Inc.
SNDXHealthcareNASDAQBiotechnology · Last scanned Jun 3, 2026
Scan Results
Daily timeframeSyndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company carries a $1.63B market cap, placing it firmly in the small-cap category. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease.
Market Cap
$1.63B
Beta
0.41
P/E (TTM)
—
P/E (Fwd)
-39.08
EPS (TTM)
$-2.79
EPS (Fwd)
$-0.47
ROE
-189.5%
ROA
-25.1%
Cash
$361.2M
Total Debt
$345.4M
Free CF
-$186.0M
52W Change
67.8%
Annual Financials
Cash vs Debt
Syndax Pharmaceuticals, Inc. holds $361.2M in cash against $345.4M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$186.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -189.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The relatively low beta of 0.41 suggests SNDX is a less volatile holding compared to the broader index. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing SNDX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.